

Javier Crespo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1555925/publications.pdf>

Version: 2024-02-01

243
papers

10,468
citations

53660

45
h-index

39575

94
g-index

256
all docs

256
docs citations

256
times ranked

13043
citing authors

#	ARTICLE	IF	CITATIONS
1	Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2. <i>Journal of Biological Chemistry</i> , 2003, 278, 5509-5512.	1.6	1,473
2	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	1.8	1,157
3	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 394, 2184-2196.	6.3	818
4	Gene expression of tumor necrosis factor [alpha] and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. <i>Hepatology</i> , 2001, 34, 1158-1163.	3.6	572
5	Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. <i>Gastroenterology</i> , 2006, 131, 451-460.	0.6	361
6	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
7	Lipopolysaccharide-Binding Protein Plasma Levels and Liver TNF-Alpha Gene Expression in Obese Patients: Evidence for the Potential Role of Endotoxin in the Pathogenesis of Non-Alcoholic Steatohepatitis. <i>Obesity Surgery</i> , 2007, 17, 1374-1380.	1.1	234
8	Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2017, 152, 1449-1461.e7.	0.6	209
9	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017, 66, 1138-1148.	1.8	159
10	Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. <i>Hepatology Communications</i> , 2018, 2, 807-820.	2.0	117
11	Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial. <i>Gastrointestinal Endoscopy</i> , 1999, 49, 417-423.	0.5	109
12	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
13	Non-alcoholic Steatohepatitis (NASH) and Hepatocellular Carcinoma. <i>Obesity Surgery</i> , 2005, 15, 442-446.	1.1	98
14	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2017, 66, 718-723.	1.8	90
15	Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. <i>Liver International</i> , 2010, 30, 1137-1142.	1.9	87
16	Vitamin D deficiency in chronic liver disease. <i>World Journal of Hepatology</i> , 2014, 6, 901.	0.8	83
17	Are there Predictive Factors of Severe Liver Fibrosis in Morbidly Obese Patients with Non-alcoholic Steatohepatitis?. <i>Obesity Surgery</i> , 2001, 11, 254-257.	1.1	80
18	JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. <i>Gastroenterology</i> , 2020, 159, 521-533.e9.	0.6	80

#	ARTICLE	IF	CITATIONS
19	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the HepaC registry. <i>Hepatology</i> , 2017, 65, 1810-1822.	3.6	78
20	The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. <i>Nature Communications</i> , 2017, 8, 2068.	5.8	77
21	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242.	1.9	76
22	Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. <i>Nature Communications</i> , 2020, 11, 3360.	5.8	73
23	Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. <i>American Journal of Gastroenterology</i> , 2018, 113, 1639-1648.	0.2	72
24	Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. <i>Digestive Diseases and Sciences</i> , 2002, 47, 1604-1610.	1.1	71
25	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). <i>Guía de práctica clínica. Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.2	71
26	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	1.9	70
27	Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. <i>Cell Metabolism</i> , 2020, 31, 605-622.e10.	7.2	68
28	The Hypoxia-Inducible Factor 1/NOR-1 Axis Regulates the Survival Response of Endothelial Cells to Hypoxia. <i>Molecular and Cellular Biology</i> , 2009, 29, 5828-5842.	1.1	64
29	Involvement of Neuron-Derived Orphan Receptor-1 (NOR-1) in LDL-Induced Mitogenic Stimulus in Vascular Smooth Muscle Cells: Role of CREB. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 697-702.	1.1	63
30	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	6.1	62
31	Irisin, a Link among Fatty Liver Disease, Physical Inactivity and Insulin Resistance. <i>International Journal of Molecular Sciences</i> , 2014, 15, 23163-23178.	1.8	61
32	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 54-64.e1.	2.4	59
33	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	1.8	59
34	Fibulin-5 Is Up-regulated by Hypoxia in Endothelial Cells through a Hypoxia-inducible Factor-1 (HIF-1)-dependent Mechanism. <i>Journal of Biological Chemistry</i> , 2011, 286, 7093-7103.	1.6	57
35	Presence of Anti-proteinase 3 Antineutrophil Cytoplasmic Antibodies (Anti-PR3 ANCA) as Serologic Markers in Inflammatory Bowel Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 109-116.	2.9	57
36	Microparticle Shedding from Neural Progenitor Cells and Vascular Compartment Cells Is Increased in Ischemic Stroke. <i>PLoS ONE</i> , 2016, 11, e0148176.	1.1	56

#	ARTICLE	IF	CITATIONS
37	CD3+/CD45+ and SMA-Î±+ circulating microparticles are increased in individuals at high cardiovascular risk who will develop a major cardiovascular event. <i>International Journal of Cardiology</i> , 2016, 208, 147-149.	0.8	55
38	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 784-793.	1.1	55
39	NOR-1 is involved in VEGF-induced endothelial cell growth. <i>Atherosclerosis</i> , 2006, 184, 276-282.	0.4	54
40	Alcoholic Recidivism After Liver Transplantation for Alcoholic Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 1998, 26, 204-206.	1.1	53
41	Long-term survival after liver transplantation for alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 9198.	1.4	53
42	Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006, 43, 72-80.	3.6	52
43	Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. <i>Journal of Hepatology</i> , 2021, 74, 469-471.	1.8	51
44	Deregulated neddylation in liver fibrosis. <i>Hepatology</i> , 2017, 65, 694-709.	3.6	50
45	MicroRNA-145 Regulates the Differentiation of Adipose Stem Cells Toward Microvascular Endothelial Cells and Promotes Angiogenesis. <i>Circulation Research</i> , 2019, 125, 74-89.	2.0	50
46	LOXL2â€™A New Target in Antifibrogenic Therapy?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1634.	1.8	50
47	Increased soluble <scp>CD</scp>36 is linked to advanced steatosis in nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2014, 44, 65-73.	1.7	49
48	Severe clinical course of de novo hepatitis B infection after liver transplantation. <i>Liver Transplantation</i> , 1999, 5, 175-183.	1.9	48
49	Binge drinking: Burden of liver disease and beyond. <i>World Journal of Hepatology</i> , 2015, 7, 2703.	0.8	46
50	Hepatic p63 regulates steatosis via IKKÎ²/ER stress. <i>Nature Communications</i> , 2017, 8, 15111.	5.8	45
51	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 106, 55-67.	0.9	45
52	PCSK9 and LRP5 in macrophage lipid internalization and inflammation. <i>Cardiovascular Research</i> , 2021, 117, 2054-2068.	1.8	45
53	Liver transplantation with allografts from hepatitis B core antibody-positive donors: A new approach. <i>Liver Transplantation</i> , 2003, 9, 916-920.	1.3	42
54	Endothelial progenitor cells in acute ischemic stroke. <i>Brain and Behavior</i> , 2013, 3, 649-655.	1.0	42

#	ARTICLE	IF	CITATIONS
55	Increased expression of Ob-Rb and its relationship with the overexpression of TGF- β 1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2006, 26, 1065-1071.	1.9	41
56	An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 275-282.	0.1	41
57	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. <i>Psychopharmacology</i> , 2016, 233, 3947-3952.	1.5	40
58	NOR-1 modulates the inflammatory response of vascular smooth muscle cells by preventing NF- κ B activation. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 80, 34-44.	0.9	39
59	Liquid Biopsy of Extracellular Microvesicles Maps Coronary Calcification and Atherosclerotic Plaque in Asymptomatic Patients With Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 945-955.	1.1	39
60	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
61	Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. <i>Journal of Viral Hepatitis</i> , 2020, 27, 360-370.	1.0	39
62	Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1662-1666.e1.	2.4	38
63	MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. <i>Cell Death and Disease</i> , 2018, 9, 958.	2.7	38
64	Congestive Hepatopathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9420.	1.8	37
65	Oxidized Low-Density Lipoprotein Receptor in Lymphocytes Prevents Atherosclerosis and Predicts Subclinical Disease. <i>Circulation</i> , 2019, 139, 243-255.	1.6	36
66	Diagnosis, treatment and long-term outcomes of autoimmune pancreatitis in Spain based on the International Consensus Diagnostic Criteria: A multi-centre study. <i>Pancreatology</i> , 2016, 16, 382-390.	0.5	35
67	miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. <i>Molecular Metabolism</i> , 2019, 29, 40-54.	3.0	35
68	Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 11016.	1.4	35
69	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 31421.	1.6	33
70	Liquid Biopsy of Extracellular Microvesicles Predicts Future Major Ischemic Events in Genetically Characterized Familial Hypercholesterolemia Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1172-1181.	1.1	31
71	Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis. <i>Journal of Hepatology</i> , 2022, 77, 15-28.	1.8	31
72	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. <i>Hepatology</i> , 2022, 76, 1121-1134.	3.6	31

#	ARTICLE	IF	CITATIONS
73	Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project. <i>Hepatology</i> , 2014, 60, 106-113.	3.6	29
74	The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	29
75	Metabolic effects of reduced growth hormone action in fatty liver disease. <i>Hepatology International</i> , 2018, 12, 474-481.	1.9	29
76	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019, 7, 825-837.	1.6	29
77	Chemoprophylaxis with isoniazid in liver transplant recipients. <i>Liver Transplantation</i> , 2012, 18, 1110-1117.	1.3	28
78	HMG-CoA reductase inhibition prior reperfusion improves reparative fibrosis post-myocardial infarction in a preclinical experimental model. <i>International Journal of Cardiology</i> , 2014, 175, 528-538.	0.8	28
79	CD142+/CD61+, CD146+ and CD45+ microparticles predict cardiovascular events in high risk patients following a Mediterranean diet supplemented with nuts. <i>Thrombosis and Haemostasis</i> , 2016, 116, 103-114.	1.8	28
80	Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1878.	1.8	28
81	A morphological method for ammonia detection in liver. <i>PLoS ONE</i> , 2017, 12, e0173914.	1.1	28
82	Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. <i>Cardiovascular Research</i> , 2005, 67, 333-341.	1.8	27
83	E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. <i>Cancer Research</i> , 2021, 81, 2874-2887.	0.4	27
84	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 779-789.	1.1	25
85	Eliminaci3n de la hepatitis C. Documento de posicionamiento de la Asociaci3n Espaola para el Estudio del HAgado (AEEH). <i>GastroenterologA Y HepatologA</i> , 2019, 42, 579-592.	0.2	25
86	Sleep Apnea Obstructive Syndrome: A New Complication Previously Undescribed in Cirrhotic Patients With Ascites. <i>American Journal of Gastroenterology</i> , 2003, 98, 2815-2816.	0.2	24
87	Circulating Endothelial Progenitor Cells and the Risk of Vascular Events after Ischemic Stroke. <i>PLoS ONE</i> , 2015, 10, e0124895.	1.1	24
88	Eliminaci3n de la hepatitis C en EspaAa: adaptaci3n de un modelo matemAtico de salud pAblica partiendo del plan estratAgico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. <i>Medicina ClAnica</i> , 2017, 148, 277-282.	0.3	24
89	Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 406-414.e7.	2.4	23
90	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 945-949.e1.	2.4	22

#	ARTICLE	IF	CITATIONS
91	Silybum marianum provides cardioprotection and limits adverse remodeling post-myocardial infarction by mitigating oxidative stress and reactive fibrosis. <i>International Journal of Cardiology</i> , 2018, 270, 28-35.	0.8	22
92	A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. <i>Journal of Clinical Medicine</i> , 2020, 9, 1369.	1.0	22
93	Telemedicine efficiently improves access to hepatitis C management to achieve HCV elimination in the penitentiary setting. <i>International Journal of Drug Policy</i> , 2021, 88, 103031.	1.6	22
94	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. <i>Molecular Metabolism</i> , 2021, 53, 101275.	3.0	22
95	Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. <i>American Journal of Gastroenterology</i> , 2004, 99, 2150-2157.	0.2	21
96	Liquid Biopsies: Microvesicles in Cardiovascular Disease. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 645-662.	2.5	21
97	Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH. <i>Journal of Hepatology</i> , 2021, 75, 34-45.	1.8	21
98	Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 95, 109677.	2.5	20
99	COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 389-396.	0.1	20
100	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015, 62, 1246-1255.	1.8	19
101	El diagn3stico de la infecci3n por el virus de la hepatitis C en Espa±a: una oportunidad para mejorar. <i>Enfermedades Infecciosas Y MicrobiologAa ClÁnica</i> , 2019, 37, 231-238.	0.3	19
102	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1627-1633.	1.4	19
103	Involvement of the Fas System in Hepatitis C Virus Recurrence After Liver Transplantation. <i>Liver Transplantation</i> , 2000, 6, 562-569.	1.3	18
104	Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3655-3667.	1.8	18
105	Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. <i>Cells</i> , 2019, 8, 1506.	1.8	18
106	Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. <i>Scientific Reports</i> , 2021, 11, 9819.	1.6	18
107	Plasma betatrophin levels in patients with liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 10662.	1.4	17
108	Características clÁnicas del carcinoma hepatocelular en Espa±a. Comparaci3n con el perÁodo 2008-2009 y anÁlisis de las causas del diagn3stico fuera de cribado. <i>Estudio de 686 casos en 73 centros. Medicina ClÁnica</i> , 2017, 149, 61-71.	0.3	17

#	ARTICLE	IF	CITATIONS
109	Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study. <i>Scientific Reports</i> , 2019, 9, 16849.	1.6	17
110	The Mediterranean diet decreases prothrombotic microvesicle release in asymptomatic individuals at high cardiovascular risk. <i>Clinical Nutrition</i> , 2020, 39, 3377-3384.	2.3	17
111	Barriers to HCV treatment in the era of triple therapy: a prospective multicentred study in clinical practice. <i>Liver International</i> , 2015, 35, 401-408.	1.9	16
112	Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences. <i>Diagnostics</i> , 2021, 11, 877.	1.3	16
113	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. <i>Journal of Hepatology</i> , 2022, 76, 11-24.	1.8	16
114	The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	15
115	Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 109, 17-25.	0.1	15
116	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018, 68, 940-948.	1.8	15
117	Stem cells from human cardiac adipose tissue depots show different gene expression and functional capacities. <i>Stem Cell Research and Therapy</i> , 2019, 10, 361.	2.4	15
118	Diagnóstico en un solo paso de la hepatitis C en 2019: una realidad en España. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 119-126.	0.3	15
119	Diet microparticles and atherothrombosis. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 432-457.	3.0	14
120	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	1.9	14
121	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015, 35, 90-100.	1.9	13
122	High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. <i>Journal of Hepatology</i> , 2019, 71, 876-888.	1.8	13
123	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	1.9	13
124	Measurement and clinical usefulness of bilirubin in liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 352-361.	0.1	13
125	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. <i>Scientific Reports</i> , 2021, 11, 24133.	1.6	13
126	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, 311-316.	1.8	12

#	ARTICLE	IF	CITATIONS
127	Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. <i>Digestive and Liver Disease</i> , 2019, 51, 95-103.	0.4	12
128	Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 267-271.	0.8	12
129	SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination. <i>Journal of Hepatology</i> , 2021, 74, 966-967.	1.8	12
130	COVID-SCORE Spain: public perceptions of key government COVID-19 control measures. <i>European Journal of Public Health</i> , 2021, 31, 1095-1102.	0.1	12
131	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. <i>United European Gastroenterology Journal</i> , 2021, 9, 892-902.	1.6	12
132	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 862-873.	0.1	12
133	Colorectal Adenomas Contain Multiple Somatic Mutations That Do Not Coincide with Synchronous Adenocarcinoma Specimens. <i>PLoS ONE</i> , 2015, 10, e0119946.	1.1	11
134	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015, 68, 56-60.	1.6	11
135	Endoscopy and sedation: an inseparable binomial for the gastroenterologist. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 250-252.	0.1	11
136	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017, 37, 1823-1832.	1.9	10
137	Is Routine Prophylaxis Against <i>Pneumocystis jirovecii</i> Needed in Liver Transplantation? A Retrospective Single-Centre Experience and Current Prophylaxis Strategies in Spain. <i>Journal of Clinical Medicine</i> , 2020, 9, 3573.	1.0	10
138	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. <i>Biomedicines</i> , 2022, 10, 46.	1.4	10
139	Prevalence estimation of significant fibrosis because of <sc>NASH</sc> in Spain combining transient elastography and histology. <i>Liver International</i> , 2022, 42, 1783-1792.	1.9	10
140	ENDOTHELIN-1 AND VASCULAR COMPLICATIONS IN LIVER TRANSPLANTATION. <i>Transplantation</i> , 1995, 59, 1748-1751.	0.5	9
141	Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. <i>Oncotarget</i> , 2018, 9, 30869-30882.	0.8	9
142	The efficiency of several one-step testing strategies for the diagnosis of hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 111, 10-16.	0.1	9
143	Adrenomedullin in liver transplantation and its relationship with vascular complications. <i>Liver Transplantation</i> , 1999, 5, 485-490.	1.9	8
144	Assessment of health sciences and science and technology librarian e-science educational needs to develop an e-science web portal for librarians. <i>Journal of the Medical Library Association: JMLA</i> , 2011, 99, 153-156.	0.6	8

#	ARTICLE	IF	CITATIONS
145	Antibody response to the messenger RNA mRNA vaccine (Moderna) in liver transplant recipients. <i>Hepatology Communications</i> , 2022, 6, 1673-1679.	2.0	8
146	Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia. <i>Hepatology</i> , 2022, 76, 1259-1274.	3.6	8
147	Ten steps to eliminating hepatitis C in hospitals. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 481-483.	8.2	8
148	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterology and Hepatology (English Edition)</i> , 2018, 41, 328-349.	0.0	7
149	Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 472.	0.7	7
150	Propionate Fermentative Genes of the Gut Microbiome Decrease in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2176.	1.0	7
151	miR-17 and -20a Target the Neuron-Derived Orphan Receptor-1 (NOR-1) in Vascular Endothelial Cells. <i>PLoS ONE</i> , 2015, 10, e0141932.	1.1	7
152	Strategy for the Elimination of Hepatitis C in Cantabria. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 565-570.	0.1	7
153	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 397-411.	0.1	7
154	Dendroaspis natriuretic peptide in hepatic cirrhosis. <i>American Journal of Gastroenterology</i> , 2001, 96, 2724-2729.	0.2	6
155	Update on epidemiology of hepatitis B in a low endemic European country: There is still much to do. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1261-1265.	1.0	6
156	Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. <i>Frontiers in Immunology</i> , 2021, 12, 651728.	2.2	6
157	Microvesicles carrying LRP5 induce macrophage polarization to an anti-inflammatory phenotype. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7935-7947.	1.6	6
158	Anti-epileptic drugs and hepatitis C therapy: Real-world experience. <i>Journal of Hepatology</i> , 2021, 75, 984-985.	1.8	6
159	Nonalcoholic Fatty Liver Disease: A Pathological View. , 0, , .		5
160	Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1242.	1.0	5
161	FRI-225-Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection. <i>Journal of Hepatology</i> , 2019, 70, e493-e494.	1.8	5
162	National digestive disease specialists survey on cardiovascular risk management in non-alcoholic fatty liver disease in spanish hospitals. <i>Liver International</i> , 2021, 41, 1243-1253.	1.9	5

#	ARTICLE	IF	CITATIONS
163	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. <i>JHEP Reports</i> , 2021, 3, 100276.	2.6	5
164	Letâ€™s leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world. <i>Journal of Hepatology</i> , 2021, 75, 224-226.	1.8	5
165	Nonâ€™malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors. <i>Hepatology Research</i> , 2021, 51, 1064-1072.	1.8	5
166	HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?. <i>Journal of Hepatology</i> , 2021, 75, 486-487.	1.8	5
167	Geographic analysis and estimation of hepatitis C cases in migrant populations living in Spain: is a country-based screening strategy appropriate?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 615-625.	0.1	5
168	SARS-CoV-2 and Liver Transplant: How Has It Behaved in This Sixth Wave?. <i>Transplantation</i> , 2022, 106, 1445-1449.	0.5	5
169	Granulocyte elastase in cirrhotic patients with spontaneous bacterial peritonitis. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1985-1989.	1.1	4
170	Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. <i>United European Gastroenterology Journal</i> , 2015, 3, 284-293.	1.6	4
171	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease. , 0, , .		4
172	Bone mineral density and trabecular bone score in treatment-naïve patients with non-cirrhotic hepatitis C virus infection. <i>Archives of Osteoporosis</i> , 2020, 15, 72.	1.0	4
173	Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 619-626.	0.1	4
174	Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 731-737.	0.1	4
175	Principles for implementing a population screening strategy for hepatitis C in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 112, 64-70.	0.1	4
176	NS5A Resistance: Clinical Implications and Treatment Possibilities. <i>AIDS Reviews</i> , 2016, 18, 15-22.	0.5	4
177	Roflumilast-induced Local Vascular Injury Is Associated with a Coordinated Proteome and Microparticle Change in the Systemic Circulation in Pigs. <i>Toxicologic Pathology</i> , 2015, 43, 569-580.	0.9	3
178	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 641-649.	0.1	3
179	FRI-217-Safety, antiviral activity, and pharmacokinetics of a novel hepatitis B virus capsid assembly modulator, JNJ-, in Asian and non-Asian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, e489-e490.	1.8	3
180	Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. <i>Annals of Hepatology</i> , 2019, 18, 236-239.	0.6	3

#	ARTICLE	IF	CITATIONS
181	HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?. <i>Current Hepatology Reports</i> , 2019, 18, 259-267.	0.4	3
182	PS-200-The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD. <i>Journal of Hepatology</i> , 2019, 70, e133-e134.	1.8	3
183	Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis. <i>Data in Brief</i> , 2019, 27, 104415.	0.5	3
184	Impact of the COVID-19 lockdown on liver transplant recipients. A single center observational study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, , .	0.1	3
185	Biochemical assessment of metabolic associated fatty liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 199-208.	0.1	3
186	Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. <i>World Journal of Clinical Cases</i> , 2018, 6, 611-623.	0.3	3
187	Epidemiology of intrafamilial inflammatory bowel disease throughout Europe. <i>Annals of Gastroenterology</i> , 2012, 25, 188-192.	0.4	3
188	Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study. <i>Schizophrenia Research</i> , 2022, 246, 30-38.	1.1	3
189	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613.	1.1	2
190	Influence of anti-TNF therapy on bone metabolism in patients with inflammatory bowel disease. <i>European Journal of Internal Medicine</i> , 2017, 39, e33-e34.	1.0	2
191	AA Amyloidosis Associated with Jugular Paraganglioma as a Rare Cause of Chronic Diarrhea. <i>ACG Case Reports Journal</i> , 2017, 4, e100.	0.2	2
192	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2019, 42, 579-592.	0.0	2
193	COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?. <i>Autoimmunity Reviews</i> , 2020, 19, 102683.	2.5	2
194	Microelimination beyond prison walls: subjects sentenced to non-custodial sentences, screening and immediate assisted treatment with "navigator" figure and telemedicine. <i>Journal of Hepatology</i> , 2020, 73, S361-S362.	1.8	2
195	The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries. <i>Digestive and Liver Disease</i> , 2020, 52, e33-e34.	0.4	2
196	Telemedicine, time to change paradigm of Hepatitis C management: improve access and reduce costs. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 623-624.	0.1	2
197	Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFNÎ³ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells. <i>Viruses</i> , 2021, 13, 635.	1.5	2
198	Triglyceride-induced cardiac lipotoxicity is mitigated by Silybum marianum. <i>Atherosclerosis</i> , 2021, 324, 91-101.	0.4	2

#	ARTICLE	IF	CITATIONS
199	In reply to: Confirmation of antibodies against hepatitis C virus by recombinant immunoblot: Is it really an improvement to abandon it?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 95.	0.3	2
200	Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy. <i>Revista Española De Enfermedades Digestivas</i> , 2015, 108, 421-30.	0.1	2
201	Hepatitis crónica por VHC en la población usuaria de drogas por vía parenteral. Motivos para no iniciar el tratamiento antiviral. <i>Revista De Psicología De La Salud</i> , 2001, 13, 399.	0.2	2
202	Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. <i>Revista Española De Enfermedades Digestivas</i> , 2020, 112, 778-783.	0.1	2
203	Digestive units in the National Health System of the 21st century. Organizational and management standards for a patient-centered service. <i>Revista Española De Enfermedades Digestivas</i> , 2020, 112, 144-149.	0.1	2
204	Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas». <i>Gastroenterología Y Hepatología</i> , 2023, 46, 236-247.	0.2	2
205	Coagulation Disorders in Acute Lung Injury. <i>Current Respiratory Medicine Reviews</i> , 2009, 5, 149-159.	0.1	1
206	Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. <i>Gastroenterología Y Hepatología</i> , 2013, 36, 555-564.	0.2	1
207	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015, 14, 477-486.	0.6	1
208	Computerized Physician Order Entry-Based System Improves Hepatitis B Virus Screening in Patients Undergoing Chemotherapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 290-290.	0.8	1
209	Resistencia al virus de la hepatitis C. Implicaciones y posibilidades terapéuticas. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 484-494.	0.2	1
210	Ascites: Treatment, Complications, and Prognosis. , 2017, , .		1
211	Reply to the letter by Dr. Ulas to the manuscript entitled: «Silybum marianum provides cardioprotection and limits adverse remodeling post-myocardial infarction by mitigating oxidative stress and reactive fibrosis». <i>International Journal of Cardiology</i> , 2018, 270, 78.	0.8	1
212	FRI-343-NEDDylation inhibition as a new potential therapy of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 70, e546.	1.8	1
213	PS-015-Role of methylation-controlled J-protein, endogenous repressor of the mitochondrial respiratory chain, in cholestatic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e12.	1.8	1
214	An Elusive Diagnosis in Noncirrhotic Chronic Portal Vein Thrombosis. <i>American Journal of Medicine</i> , 2021, 134, e199-e200.	0.6	1
215	Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 209-219.	0.1	1
216	Targeting Hepatic Glutaminase 1 Ameliorates Non-Alcoholic Steatohepatitis by Restoring Disrupted Hepatic Very-Low Density Lipoproteins Triglyceride Assembly. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
217	Shadows in the current management of hepatocellular carcinoma in Spain - An embarrassing truth. Revista Espanola De Enfermedades Digestivas, 2019, 111, 727-730.	0.1	1
218	Author's answer to: Effect of adacolumnin in ulcerative colitis with COVID-19. Revista Espanola De Enfermedades Digestivas, 2020, 112, 511-512.	0.1	1
219	Can NAFLD overwhelm the Spanish healthcare system in the years to come?. Revista Espanola De Enfermedades Digestivas, 2021, 114, 5-9.	0.1	1
220	Dendroaspis natriuretic peptide in hepatic cirrhosis. American Journal of Gastroenterology, 2001, 96, 2724-2729.	0.2	0
221	Role of transforming growth factor B (TGF-B) in hepatic fibrosis of non-alcoholic steatohepatitis (NASH) patients. Journal of Hepatology, 2002, 36, 69.	1.8	0
222	TNF-alpha and TNF-alpha receptors serum levels do not correlate with gene expression of TNF-alpha and their receptors in the non-alcoholic steatohepatitis (NASH) patients. Journal of Hepatology, 2002, 36, 69.	1.8	0
223	Chemokine expression in non-alcoholic steatohepatitis. Gastroenterology, 2003, 124, A744.	0.6	0
224	Sleep Apnea Obstructive Syndrome: A New Complication Previously Undescribed in Cirrhotic Patients with Ascites: Response to Drs. Golpe and Mateos. American Journal of Gastroenterology, 2005, 100, 1423-1423.	0.2	0
225	Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver International, 2015, 35, 1775-1775.	1.9	0
226	Resistance to hepatitis C virus. Implications and therapeutic options. GastroenterologĀa Y HepatologĀa (English Edition), 2017, 40, 484-494.	0.0	0
227	A Rare But Recognizable Cholestatic Liver Disease. Gastroenterology, 2018, 155, e17-e19.	0.6	0
228	THU-293-Increased risk of advanced liver disease independently of classic metabolic risk factors or drug induced hepatotoxicity in patients with psoriasis. Journal of Hepatology, 2019, 70, e289.	1.8	0
229	FRI-373-Mismatch in C-locus Eplets between donor and recipient as independent factor of acute T-cell mediated rejection in liver transplantation. Journal of Hepatology, 2019, 70, e558-e559.	1.8	0
230	SAT-296-Oxidized LDL is a distinctive biomarker of NASH independently of liver fibrosis in patients with NAFLD. Journal of Hepatology, 2019, 70, e768-e769.	1.8	0
231	FRI-294-Mitochondrial GNMT-complex II is recovered by miR-873-5p targeting in NAFLD. Journal of Hepatology, 2019, 70, e524-e525.	1.8	0
232	SAT-256-Influence of metabolic syndrome on fibrosis regression regulated by LOXL-2 after SVR. Journal of Hepatology, 2019, 70, e746.	1.8	0
233	THU-124-Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C). Journal of Hepatology, 2019, 70, e213-e214.	1.8	0
234	Diagnosis of hepatitis C virus infection in Spain: An opportunity to improve. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 231-238.	0.2	0

#	ARTICLE	IF	CITATIONS
235	E104â€fApremilast, psoriasis and psoriatic arthritis and chronic liver disease. Rheumatology, 2019, 58, .	0.9	0
236	Hepatitis C reflex testing in Spain in 2019: A story of success. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2021, 39, 119-126.	0.2	0
237	Bilirrubina: MediciÃ³n y utilidad clÃ¡nica en la enfermedad hepÃ¡tica. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 362-372.	0.1	0
238	SARS-CoV-2 detection by self-testing: A method to improve surveillance programmes. GastroenterologÃ­a Y HepatologÃ­a, 2021, 44, 395-397.	0.2	0
239	Gastroenterology, a historical specialty with a great future. Revista Espanola De Enfermedades Digestivas, 2017, 109, 611-613.	0.1	0
240	Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. Annals of Hepatology, 2018, 17, 0-10.	0.6	0
241	Overall clinical and economic impact of non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2020, 113, 396-403.	0.1	0
242	Relationship between gastroenterologists and hospital pharmacists: the results of a national survey. The CONDIFA study. Revista Espanola De Enfermedades Digestivas, 2020, 112, 675-681.	0.1	0
243	Biopsy for hepatocellular carcinoma: only occasionally. Revista Espanola De Enfermedades Digestivas, 2020, 112, 666-667.	0.1	0